Dynavax Technologies' (DVAX) "Sell (D)" Rating Reiterated at Weiss Ratings

Key Points

• Weiss Ratings has reiterated a "sell (D)" rating for Dynavax Technologies (DVAX), which indicates continued skepticism about the company's stock performance.
• Despite the "sell" rating, Wall Street Zen upgraded the stock from "hold" to "buy" recently, while JMP Securities set a target price of $32.00.
• Dynavax Technologies reported a quarterly earnings per share of $0.14, surpassing analysts' expectations, with revenue reaching $95.44 million for the same period.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report)'s stock had its "sell (d)" rating reiterated by Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Other equities analysts also recently issued reports about the stock. Wall Street Zen raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. JMP Securities reissued a "market outperform" rating and set a $32.00 target price on shares of Dynavax Technologies in a research report on Friday, August 22nd. Three research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, Dynavax Technologies presently has a consensus rating of "Hold" and a consensus price target of $24.33.

Dynavax Technologies Stock Up 0.4%

Shares of NASDAQ:DVAX traded up $0.04 during midday trading on Wednesday, hitting $10.18. 1,392,794 shares of the stock were exchanged, compared to its average volume of 1,724,125. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65. Dynavax Technologies has a 52-week low of $9.20 and a 52-week high of $14.63. The business's fifty day simple moving average is $10.21 and its two-hundred day simple moving average is $10.60. The company has a market capitalization of $1.19 billion, a PE ratio of -22.13 and a beta of 1.13.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.12 by $0.02. The firm had revenue of $95.44 million for the quarter, compared to the consensus estimate of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. As a group, research analysts predict that Dynavax Technologies will post 0.32 earnings per share for the current fiscal year.

Insider Buying and Selling at Dynavax Technologies

In related news, Director Scott Dunseth Myers purchased 3,800 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was acquired at an average price of $10.82 per share, with a total value of $41,116.00. Following the completion of the acquisition, the director directly owned 35,004 shares in the company, valued at approximately $378,743.28. This trade represents a 12.18% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.98% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Dynavax Technologies

Several institutional investors and hedge funds have recently made changes to their positions in DVAX. Osaic Holdings Inc. lifted its position in Dynavax Technologies by 15.1% in the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company's stock valued at $93,000 after acquiring an additional 1,226 shares in the last quarter. Squarepoint Ops LLC grew its stake in Dynavax Technologies by 222.3% in the 2nd quarter. Squarepoint Ops LLC now owns 435,577 shares of the biopharmaceutical company's stock valued at $4,321,000 after buying an additional 300,421 shares during the last quarter. State of Wyoming acquired a new position in Dynavax Technologies in the 2nd quarter valued at about $304,000. Hudson Bay Capital Management LP grew its position in shares of Dynavax Technologies by 46.4% during the 2nd quarter. Hudson Bay Capital Management LP now owns 541,600 shares of the biopharmaceutical company's stock worth $5,373,000 after purchasing an additional 171,700 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its position in shares of Dynavax Technologies by 319.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 16,239 shares of the biopharmaceutical company's stock worth $161,000 after purchasing an additional 12,371 shares in the last quarter. Institutional investors and hedge funds own 96.96% of the company's stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.